Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has voluntarily given written informed consent (before conduct of any study-related procedures)~* The subject has hereditary type 3 VWD (\<= 3 IU/dL VWF:Ag)or severe type 1 or type 2A VWD (VWF:RCo \<= 10% and FVIII:C \<20%)~* The subject has a medical history of at least 25 exposure days to VWF/FVIII coagulation factor concentrates~* The subject has a Karnofsky score \>= 70%~* The subject is between 18 to 60 years of age (on the day of signing the informed consent)~* NOT APPLICABLE IN ITALY: Female subjects of child-bearing potential must have a negative pregnancy test and agree to practice contraception using a method of proven reliability from the day of screening until the study completion visit~* APPLICABLE ONLY IN ITALY: Female subjects of child-bearing potential must have a negative pregnancy test and agree to practice non-hormonal-based contraception using a method of proven reliability (IUD acceptable) from the day of screening until 96 hours after the last investigational drug infusion~* NOT APPLICABLE IN ITALY: The subject must agree not to be on any therapy (hormone-based contraception acceptable) interfering with coagulation factor pharmacokinetics until 96 hours after the last investigational drug infusion~* APPLICABLE ONLY IN ITALY: The subject must agree not to be on any therapy interfering with coagulation factor pharmacokinetics until 96 hours after the last investigational drug infusion~Exclusion Criteria:~* The subject has been diagnosed with a hereditary or acquired coagulation disorder other than VWD (including qualitative and quantitative platelet disorders and/or an international normalized ratio (INR) \> 1.4)~* The subject has been diagnosed with an ADAMTS13 deficiency with less than 10% ADAMTS13 activity~* The subject has a history or presence of VWF inhibitor~* The subject has a history or presence of FVIII inhibitor with a titer \>= 0.4 BU (by Nijmegen assay) or \>= 0.6 BU (by Bethesda assay)~* The subject has a known hypersensitivity to mouse or hamster proteins~* The subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, food allergies or animal allergies~* The subject has a medical history of a thromboembolic event~* The subject is HIV positive with an absolute CD4 count \< 200/mm3~* The subject has been diagnosed with cardiovascular disease (New York Heart Association (NYHA) classes 1-4)~* The subject has been diagnosed with insulin-dependent diabetes mellitus~* The subject has an acute illness (e.g. influenza, flu-like syndrome, allergic rhinitis/conjunctivitis)~* The subject has been diagnosed with liver disease, as evidenced by, but not limited to, any of the following: serum ALT three times the upper limit of normal, hypoalbuminemia, portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices)~* The subject has been diagnosed with renal disease, with a serum creatinine level \>= 2 mg/dL~* In the judgment of the investigator, the subject has another clinically significant concomitant disease (e.g. uncontrolled hypertension, diabetes type II) that may pose additional risks for the subject~* The subject has been treated with an immunomodulatory drug, excluding topical treatment (e.g. ointments, nasal sprays) within 30 days before enrollment~* The subject has been treated with drugs known to induce thrombotic thrombocytopenic purpura (TTP) (e.g. Adenosine diphosphate (ADP) receptor inhibitors (Clopidogrel, Ticlopidine)) within 60 days before enrollment~* The subject is receiving or anticipates receiving another investigational and/or interventional drug within 30 days before enrollment~* The subject is a lactating female~* The subject has a history of drug or alcohol abuse within the last 5 years~* The subject has a progressive fatal disease and/or life expectancy of less than 3 months~* The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures~* The subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude~* Subject is in prison or compulsory detention by regulatory and/or juridical order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete